Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Feb 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cabiralizumab (Primary) ; Nivolumab (Primary) ; Urelumab (Primary)
Indications Advanced breast cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man
Acronyms C4-MOSART

17 Feb 2023 Status changed from active, no longer recruiting to completed.
14 Mar 2022 Planned End Date changed from 1 Feb 2022 to 1 Jul 2022.
24 Jun 2021 Results evaluating safety and efficacy of SBRT with nivolumab+urelumab (CD137 agonist) or nivolumab+cabiralizumab published in the Clinical Cancer Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com